Evidence map›Paper›PMID 40019651›Full record

ArticleDrug delivery and translational research2025

Chitosan-Artesunate nanoparticles: A dual anti-fibrotic and anti-inflammatory strategy for preventing bleb fibrosis post-glaucoma filtration surgery.

Jingyuan Liu, Shutong Wang, Guangshuang Tan, Boding Tong, Ying Wu, Lusi Zhang, Bing Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jingyuan LiuDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China.ORCID 0009-0007-1300-4835
Shutong WangDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China.
Guangshuang TanDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China.
Boding TongDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China.
Ying WuDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China.
Lusi ZhangDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China. Zhanglusi@csu.edu.cn.
Bing JiangDepartment of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410000, Hunan, China. drJiangb@csu.edu.cn.

Funding

Changsha Science and Technology Project kq2403080Key Research and Development Program of Hunan Province of China 2023SK2029National Natural Science Foundation of China 82070967
6 · The paper itself

Abstract

Glaucoma filtration surgery (GFS) effectively lowers intraocular pressure in glaucoma patients, but postoperative bleb fibrosis often leads to surgical failure. Artesunate (ART) has demonstrated antifibrotic potential; however, its clinical use is limited by poor solubility and rapid degradation. This study aimed to develop chitosan-ART nanoparticles (CS@ART NPs) to improve ART's therapeutic efficacy in preventing bleb fibrosis. CS@ART NPs were synthesized using an ionic gelation method for chitosan encapsulation. Their characterization, including analyses of morphology, hydrodynamic properties, surface charge, encapsulation efficiency, drug release kinetics, stability, chemical structure, and mucoadhesive interactions, was carried out using various techniques such as TEM, DLS, zeta potential analysis, HPLC, FT-IR,

Indexed as

Antifibrotic AgentsAnti-Inflammatory AgentsArtesunateChitosanFiltering SurgeryGlaucomaNanoparticlesAnimalsCell ProliferationCells, CulturedDrug LiberationFibroblastsFibrosisHumansMaleRabbitsAntifibrotic AgentsAnti-Inflammatory AgentsArtesunateChitosanArtesunateChitosan nanoparticlesGlaucoma filtration surgeryOcular fibrosis

Identifiers

PMID40019651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.